Biomerieux Inc.

Biomerieux Inc., operating through its Vitek Systems, Inc. division, manufactures in vitro diagnostic equipment, reagents, test kits, and microbiological testing consumables for federal healthcare agencies as a prime contractor on full-and-open, sole-source contracts carrying no set-aside designations. The company is a for-profit corporate entity headquartered in Salt Lake City, Utah, with a subsidiary, Biofire Diagnostics LLC. Biomerieux competes across all-small-business and unrestricted competitive space, competing predominantly as a sole-source provider of proprietary diagnostic platforms rather than through formal set-aside categories.

Biomerieux's capability portfolio centers on specialized in vitro diagnostic platforms and consumables. The company supplies microorganism identification and antibiotic susceptibility testing systems (VITEK platform), molecular multiplex PCR pathogen detection solutions (BioFire platform), automated blood culture analyzers and incubators, immunoassay systems (VIDAS platform), and associated reagents, test kits, and preventive maintenance services. Recent representative work includes a $4.29 million five-year delivery order from Veterans Integrated Service Network 17 for BioFire analyzer reagents issued January 20, 2026, a $3.68 million delivery order from the Food and Drug Administration for VIDAS KUBE diagnostic systems issued September 15, 2026, a $3.25 million delivery order from VISN 15 for BioFire TORCH systems and reagents issued October 1, 2025, a $37 million indefinite delivery contract from VISN 9 for comprehensive diagnostic equipment and services established May 29, 2026, and a $7.74 million blanket purchase agreement from VISN 1 for BioFire reagents and test panels established August 18, 2026.

Customer concentration reflects heavy reliance on the Department of Veterans Affairs. The top five customer agencies by combined potential value account for 42 percent of Biomerieux's recent award dollars, led by VISN 12 (229 awards, $283.7 million potential value), VISN 8 (156 awards, $72 million), VISN 22 (160 awards, $66.5 million), VISN 15 (148 awards, $64.7 million), and VISN 9 (158 awards, $50.8 million). Award count and potential-value rankings diverge sharply—VISN 12 commands most dollars despite not appearing in the top five by award count, reflecting large contract vehicles serving that network, while Indian Health Service (411 awards) and Bureau of Medicine and Surgery (338 awards) place high on volume but lower on total dollars. Together, VA networks dominate the footprint, with the department representing the overwhelming majority of the portfolio.

Biomerieux seats on five parent GSA and federal vehicles. The Critical Analyzers, Laboratory schedule (FSS-66-III) carries 1,621 task orders with $130 million combined potential value, supporting automated blood culture and microorganism identification testing across multiple agencies. The Multiple Award Schedule (MAS) supports 1,073 task orders worth $69.6 million, enabling broad federal agency access to diagnostic platforms and consumables. The Federal Supply Schedule for In Vitro Diagnostics, Reagents, and Test Kits (FSS-65-VII) has generated 148 task orders totaling $148.9 million in potential value. Two agency-specific IDIQs anchor significant work: VISN 9's comprehensive Biomerieux indefinite delivery contract ($37 million ceiling), and VISN 12's polymerase chain reaction services BPA (not separately itemized but supporting substantial annual ordering). Activity has grown modestly year over year—202 awards in 2022 to 259 in 2025—with 152 awards (combined potential value $55.4 million) scheduled for completion inside the next twenty-four months and therefore facing recompete exposure.

The Service Contract Inventory dataset captures a limited slice of Biomerieux's federal work: 36 SCI-reportable prime records across FY2022–FY2025, generating $1.2 million in SCI-invoiced revenue by FY2024, with 2.8 FTEs delivering services in that fiscal year. SCI does not capture the company's dominant business—goods (diagnostic equipment and reagents, test kits, consumables) and product sales, which dominate the footprint—making the SCI view a material understatement of federal services activity. On the SCI records present, median government-paid hourly rates ran around $289.55/hr, with senior labor pricing ranging to $367.60/hr, suggesting technical and scientific staffing delivering maintenance and specialized diagnostic support. Biomerieux performed 100 percent of its SCI-reportable service hours in-house across prime contracts, with zero sub-hours recorded, indicating a direct-delivery model on the limited service work captured in the dataset.

Biomerieux operates as a pure prime contractor; 100 percent of awards in the portfolio are prime contracts or grants, with only two sub-award records present. The company does not appear as a named subcontractor under larger primes in the source material, positioning it as a specialized sole-source supplier rather than a feeder to defense integrators or larger system primes. Its corporate structure includes Biofire Diagnostics LLC as a named subsidiary, reflecting the company's organization around its proprietary BioFire molecular diagnostic platform. Federal agencies award Biomerieux contracts consistently without competitive set-asides or restrictions, reflective of the company's monopoly position on proprietary diagnostic systems—agencies cannot source VITEK, BioFire, or VIDAS consumables and maintenance from competitors without losing equipment compatibility and OEM warranty coverage, driving all work to Biomerieux as an incumbent sole-source provider across nearly every Veterans Affairs network, the Indian Health Service, Defense Health Agency, and civilian federal research and public health laboratories.